Dopamine transporter (DAT) and glucose metabolism imaging have been applied in the diagnosis of Parkinson's disease (PD). We explored the possibility of evaluating for PD with NeuroQ software by analyzing C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane (C-CFT) and F-FDG PET/CT. We retrospectively analyzed brain C-CFT and F-FDG PET/CT of 38 patients with parkinsonism, including 20 with PD, 10 with multiple system atrophy (MSA) and 8 with essential tremor (ET), and compared them with the PET/CT of 11 normal healthy controls (NC). PD patients were divided into mild and moderate-severe grade according to the Hoehn-Yahr (H&Y) scale. The C-CFT uptake in the caudate nuclei (CN) and putamen (Pu) normalized with cerebellum (CN/Cb and Pu/Cb) were obtained with a manual method and NeuroQ software, and their diagnostic performance was compared.F-FDG uptake of specific regions was also obtained with NeuroQ, and the enhancement effect for the differential diagnosis was evaluated. There was significant agreement between the manual method and the NeuroQ method for C-CFT uptake by CN ( = 0.680) and Pu ( = 0.770). C-CFT uptake by CN and Pu in PD and MSA patients was significantly lower compared to NC and ET patients. The cutoffs of CN/Cb and Pu/Cb for the distinction between PD and NC were 1.71 and 2.20, respectively. No difference in uptake ratios occurred between PD and MSA. F-FDG uptake by the pons and cerebellum in the MSA group was markedly decreased. It was highly accurate in distinguishing between PD and MSA when combined with analysis of C-CFT uptake. Pu/Cb decreased significantly in mild grade PD compared to NC group (1.92 ± 0.33 vs. 2.82 ± 0.43); however no statistically significant decrease in CN/Cb was observed until moderate-severe grade PD (1.43 ± 0.11 vs. 2.23 ± 0.36). In early asymmetric PD, a statistically significant difference could be seen with Pu/Cb between the symptomatic and asymptomatic side (2.17 ± 0.30 vs. 1.95 ± 0.22). C-CFT and F-FDG PET/CT can be analyzed quantitatively with NeuroQ software, which provides an accurate method for the diagnosis and severity evaluation of PD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460224PMC
http://dx.doi.org/10.3389/fnins.2019.00299DOI Listing

Publication Analysis

Top Keywords

c-cft f-fdg
16
neuroq software
16
c-cft uptake
16
f-fdg pet/ct
12
parkinson's disease
8
moderate-severe grade
8
cn/cb pu/cb
8
manual method
8
method neuroq
8
c-cft
7

Similar Publications

Article Synopsis
  • Positron emission tomography/computed tomography (PET/CT) is a key imaging technique used to diagnose and differentiate Parkinson's disease (PD) from similar disorders in this study involving 220 patients with PD-like symptoms.
  • The study assessed the effectiveness of two tracers, C-2β-Carbomethoxy-3β-(4-fluorophenyl) tropane (C-CFT) and F-fluorodeoxyglucose (F-FDG), in distinguishing between PD, multiple system atrophy parkinsonian type (MSA-P), progressive supranuclear palsy (PSP), and vascular parkinsonism (VP).
  • Results indicated that PSP patients had the lowest C-C
View Article and Find Full Text PDF
Article Synopsis
  • * The study analyzed 51 MSA patients and 20 healthy controls using F-FDG and C-CFT PET scans to examine brain glucose metabolism and dopaminergic function, distinguishing between patients with and without OH.
  • * Results indicated significant metabolic differences in specific brain regions associated with OH in MSA patients, alongside reduced dopaminergic function, suggesting these brain changes may contribute to the symptom of OH.
View Article and Find Full Text PDF

Objectives: To construct a machine learning model for differentiating Parkinson's disease (PD) and multiple system atrophy (MSA) by using multimodal PET/MRI radiomics and clinical characteristics.

Methods: One hundred and nineteen patients (81 with PD and 38 with MSA) underwent brain PET/CT and MRI to obtain metabolic images ([F]FDG, [C]CFT PET) and structural MRI (T1WI, T2WI, and T2-FLAIR). Image analysis included automatic segmentation on MRI, co-registration of PET images onto the corresponding MRI.

View Article and Find Full Text PDF

Aim: Parkinson's disease is one of the most common neurodegenerative diseases. Excellent levodopa responsiveness has been proposed as a characteristic supporting feature in substantiating the PD diagnosis. However, a small portion of clinically established PD patients shows poor levodopa response.

View Article and Find Full Text PDF

Introduction: Parkinson's disease (PD) is a neurodegenerative disorder that affects millions of people worldwide. Subthalamic nucleus (STN) deep brain stimulation (DBS) has been shown to be an effective treatment for PD; however, the effects of this surgery on cerebral metabolism and presynaptic dopamine transporter (DAT) distribution are still being studied.

Methods: In this study, we included 12 PD patients (6 male and 6 female) who underwent STN-DBS surgery and had both F-FDG and C-CFT PET/CT imaging before and 1 year after the surgery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!